BioSeek – EPA ToxCastTM Program




          Bridging the Gap From In Vitro to In Vivo




1
EPA ToxCastTM Program

      EPA ToxCastTM Program
          Program to develop a cost-effective approach for efficiently
           prioritizing the toxicity testing of thousands of chemicals
          BioSeek has been a contractor since 2007

      Three Phases
          Phase I – Proof-of-concept
          Phase II – Verification / Extension
          Phase III – Reduction to Practice

      http://www.epa.gov/ncct/toxcast/
2
ToxCastTM Program Timeline




3
ToxCastTM Program Details

                  Number of       Chemical                           Number of   Cost per   Target
        Phase                                        Purpose
                  Chemicals        Criteria                           Assays     Chemical    Date
                                  Data Rich          Signature
             I       320                                                552        $20k      FY08
                                 (pesticides)       Development


            Ib       15         Nanomaterials           Pilot           166        $10K      FY09


                                  Data Rich
            IIa     >300                             Validation        >400      ~$20-25k    FY09
                                  Chemicals


                                Known Human
            IIb     >100                            Extrapolation      >400      ~$20-25k    FY09
                                  Toxicants


                              Expanded Structure
            IIc     >300                             Extension         >400      ~$20-25k    FY10
                               and Use Diversity


            IId      >12        Nanomaterials           PMN            >200      ~$15-20K   FY09-10

                                                   Prediction and
            III   Thousands       Data poor                            >300      ~$15-20k   FY11-12
                                                    Prioritization




7/23/2012                                          CONFIDENTIAL
4
BioSeek ToxCastTM Data
    Now Posted on EPA’s ACToR Public Database

                                                     http://actor.epa.gov/




      ACToR
      Aggregated Computational Toxicology Resource
5
BioMAP® Analysis of ToxCastTM Phase I Chemicals
    Diversity of Mechanisms Distinguished



      NFB

                                                                        cAMP Elevation




    DNA Alkylation                                                Mitochondrial Dysfunction




Reference: Houck, K.A., D.J. Dix, R.S. Judson, R.J. Kavlock, J.
Yang and E.L. Berg. 2009. Profiling bioactivity of the ToxCast     Tubulin Inhibition
chemical library using BioMAP primary human cell systems. J.
Biomol. Screen, 2009, 14:1054-66.
6
BioMAP Endpoints (BSK) in Predictive Signatures
    Rat & Rabbit Developmental Toxicity

                     Knudsen, T.B., Computational Toxicology and Prenatal Development, presentation for
                          the EPA's Computational Toxicology Community of Practice (8/25/2011)




7                                                                             Toxicol Sci. 2011, 124:109-27
BioMAP® Analysis of Nanomaterials
    ToxCast Phase II Chemicals




    •   Nanomaterials are active and distinguishable by composition
         •   Reference: Wang, A., E.L. Berg, M. Polokoff, J. Yang; D. Reif, N. Kleinstreuer, S. Marinakos, A.R. Badireddy,
             S. Gangwal, C. Matson, M. Wiesner, and K. Houck. Nanomaterial (NM) bioactivity profiling by ToxCast high-
             throughput screening (HTS). Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA.

8                                                   Confidential
BioMAP® Profile of Titanium Oxide Nanoparticles
    Similarity to Paclitaxel




      •   Paclitaxel – binds b-tubulin and causes microtubule stabilization
      •   TiO2 nanoparticles interfere with microtubules (PMID: 18776989)

9                                       Confidential
BioMAP® Analysis of Failed Pharma Compounds




    Nicole Kleinstreuer, Society of Toxicology Annual Meeting, March 12,
     2012, San Francisco, CA
10
Publications with BioSeek ToxCastTM Data

    Sipes NS, Martin MT, Reif DM, Kleinstreuer NC, Judson RS, Singh AV, Chandler KJ, Dix DJ, Kavlock
     RJ, Knudsen TB. Predictive models of prenatal developmental toxicity from ToxCast high-throughput
     screening data. Toxicol Sci. 2011, 124:109-27
    Knudsen, T. B., K. A. Houck, N. Sipes, A. V. Singh, R. Judson, M. T. Martin, A. Weissman, N.
     Kleinstreuer, H. M. Mortensen, D. Reif, J. R. Rabinowitz, R. W. Setzer, A. M. Richard, D. J. Dix, And R.
     J. Kavlock. Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets.
     TOXICOLOGY. Elsevier Ireland Limited, Limerick, Ireland, 282(1-2):1-15, (2011).
    Kleinstreuer, N. C., R. S. Judson, D. M. Reif, N. S. Sipes, A. V. Singh, K. J. Chandler, R. Dewoskin, D.
     J. Dix, R. J. Kavlock, And T. B. Knudsen. Environmental Impact on Vascular Development Predicted by
     High Throughput Screening. ENVIRONMENTAL HEALTH PERSPECTIVES. National Institute of
     Environmental Health Sciences (NIEHS), Research Triangle Park, NC, Online Edition:1-34, (2011).
     doi:10.1289/ehp.1103412
    Houck, K.A., D.J. Dix, R.S. Judson, R.J. Kavlock, J. Yang and E.L. Berg. 2009. Profiling bioactivity of
     the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen, 2009,
     14:1054-66.
    Judson RS, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, et al. 2009, In Vitro Screening of
     Environmental Chemicals for Targeted Testing Prioritization: The ToxCast Project. Environ Health
     Perspect 118(4): doi:10.1289/ehp.0901392

11
Presentations with BioSeek ToxCastTM Data
    Kleinstreuer, N. C., vEmbryo in silico models:Predicting vascular developmental toxicity, Wiley-
     Blackwell Symposium on Computational Embryology: Integration and Modeling of Developmental
     Mechanisms, Teratology Society 2012, June 25, 2012, Baltimore, MD.
    Wang, A., E.L. Berg, M. Polokoff, J. Yang; D. Reif, N. Kleinstreuer, S. Marinakos, A.R. Badireddy, S.
     Gangwal, C. Matson, M. Wiesner, and K. Houck. Nanomaterial (NM) bioactivity profiling by ToxCast
     high-throughput screening (HTS). Society of Toxicology Annual Meeting, March 12, 2012, San
     Francisco, CA.
    Kleinstreuer, N. C., K. Houck, R. Judson, D. Reif, P. Kothiya, M. Martin, T. Knudsen, A. Richard, M.
     Polokoff, J. Yang, E.L. Berg, R. Kavlock, and D. Dix. Biological profiling of the ToxCast Phase II
     Chemical Library in Primary Human Cell CoCulture Systems. Society of Toxicology Annual Meeting,
     March 12, 2012, San Francisco, CA.
    Houck, K., Use of primary human cell systems for creating predictive toxicology profiles. SBS Annual
     Meeting, 2009, Lille, France.
    Houck, K. Evaluation of the ToxCast™ suite of cellular and molecular assay for prediction of in vivo
     toxicity. GlobalChem, 2009, Baltimore, MD.
    Houck, K., Characteristics of the ToxCast™ In Vitro Datasets from Biochemical and Cellular Assays
     (EPA/ORD/NCCT). ToxCast™ Data Analysis Summit, May 14, 2009, RTP, NC.
12
Contacts


 BioSeek, LLC
 310 Utah, Suite 100
 South San Francisco, CA 94030
 650-416-7600
 www.bioseekinc.com
 www.BioMAPSystems.com

                                Bridging the Gap From In Vitro to In Vivo



BioSeek, LLC
310 Utah, #100
South San Francisco, CA 94080

BioSeek EPA ToxCast Program

  • 1.
    BioSeek – EPAToxCastTM Program Bridging the Gap From In Vitro to In Vivo 1
  • 2.
    EPA ToxCastTM Program  EPA ToxCastTM Program  Program to develop a cost-effective approach for efficiently prioritizing the toxicity testing of thousands of chemicals  BioSeek has been a contractor since 2007  Three Phases  Phase I – Proof-of-concept  Phase II – Verification / Extension  Phase III – Reduction to Practice  http://www.epa.gov/ncct/toxcast/ 2
  • 3.
  • 4.
    ToxCastTM Program Details Number of Chemical Number of Cost per Target Phase Purpose Chemicals Criteria Assays Chemical Date Data Rich Signature I 320 552 $20k FY08 (pesticides) Development Ib 15 Nanomaterials Pilot 166 $10K FY09 Data Rich IIa >300 Validation >400 ~$20-25k FY09 Chemicals Known Human IIb >100 Extrapolation >400 ~$20-25k FY09 Toxicants Expanded Structure IIc >300 Extension >400 ~$20-25k FY10 and Use Diversity IId >12 Nanomaterials PMN >200 ~$15-20K FY09-10 Prediction and III Thousands Data poor >300 ~$15-20k FY11-12 Prioritization 7/23/2012 CONFIDENTIAL 4
  • 5.
    BioSeek ToxCastTM Data Now Posted on EPA’s ACToR Public Database http://actor.epa.gov/ ACToR Aggregated Computational Toxicology Resource 5
  • 6.
    BioMAP® Analysis ofToxCastTM Phase I Chemicals Diversity of Mechanisms Distinguished NFB cAMP Elevation DNA Alkylation Mitochondrial Dysfunction Reference: Houck, K.A., D.J. Dix, R.S. Judson, R.J. Kavlock, J. Yang and E.L. Berg. 2009. Profiling bioactivity of the ToxCast Tubulin Inhibition chemical library using BioMAP primary human cell systems. J. Biomol. Screen, 2009, 14:1054-66. 6
  • 7.
    BioMAP Endpoints (BSK)in Predictive Signatures Rat & Rabbit Developmental Toxicity Knudsen, T.B., Computational Toxicology and Prenatal Development, presentation for the EPA's Computational Toxicology Community of Practice (8/25/2011) 7 Toxicol Sci. 2011, 124:109-27
  • 8.
    BioMAP® Analysis ofNanomaterials ToxCast Phase II Chemicals • Nanomaterials are active and distinguishable by composition • Reference: Wang, A., E.L. Berg, M. Polokoff, J. Yang; D. Reif, N. Kleinstreuer, S. Marinakos, A.R. Badireddy, S. Gangwal, C. Matson, M. Wiesner, and K. Houck. Nanomaterial (NM) bioactivity profiling by ToxCast high- throughput screening (HTS). Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA. 8 Confidential
  • 9.
    BioMAP® Profile ofTitanium Oxide Nanoparticles Similarity to Paclitaxel • Paclitaxel – binds b-tubulin and causes microtubule stabilization • TiO2 nanoparticles interfere with microtubules (PMID: 18776989) 9 Confidential
  • 10.
    BioMAP® Analysis ofFailed Pharma Compounds  Nicole Kleinstreuer, Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA 10
  • 11.
    Publications with BioSeekToxCastTM Data  Sipes NS, Martin MT, Reif DM, Kleinstreuer NC, Judson RS, Singh AV, Chandler KJ, Dix DJ, Kavlock RJ, Knudsen TB. Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol Sci. 2011, 124:109-27  Knudsen, T. B., K. A. Houck, N. Sipes, A. V. Singh, R. Judson, M. T. Martin, A. Weissman, N. Kleinstreuer, H. M. Mortensen, D. Reif, J. R. Rabinowitz, R. W. Setzer, A. M. Richard, D. J. Dix, And R. J. Kavlock. Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets. TOXICOLOGY. Elsevier Ireland Limited, Limerick, Ireland, 282(1-2):1-15, (2011).  Kleinstreuer, N. C., R. S. Judson, D. M. Reif, N. S. Sipes, A. V. Singh, K. J. Chandler, R. Dewoskin, D. J. Dix, R. J. Kavlock, And T. B. Knudsen. Environmental Impact on Vascular Development Predicted by High Throughput Screening. ENVIRONMENTAL HEALTH PERSPECTIVES. National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC, Online Edition:1-34, (2011). doi:10.1289/ehp.1103412  Houck, K.A., D.J. Dix, R.S. Judson, R.J. Kavlock, J. Yang and E.L. Berg. 2009. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen, 2009, 14:1054-66.  Judson RS, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, et al. 2009, In Vitro Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast Project. Environ Health Perspect 118(4): doi:10.1289/ehp.0901392 11
  • 12.
    Presentations with BioSeekToxCastTM Data  Kleinstreuer, N. C., vEmbryo in silico models:Predicting vascular developmental toxicity, Wiley- Blackwell Symposium on Computational Embryology: Integration and Modeling of Developmental Mechanisms, Teratology Society 2012, June 25, 2012, Baltimore, MD.  Wang, A., E.L. Berg, M. Polokoff, J. Yang; D. Reif, N. Kleinstreuer, S. Marinakos, A.R. Badireddy, S. Gangwal, C. Matson, M. Wiesner, and K. Houck. Nanomaterial (NM) bioactivity profiling by ToxCast high-throughput screening (HTS). Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA.  Kleinstreuer, N. C., K. Houck, R. Judson, D. Reif, P. Kothiya, M. Martin, T. Knudsen, A. Richard, M. Polokoff, J. Yang, E.L. Berg, R. Kavlock, and D. Dix. Biological profiling of the ToxCast Phase II Chemical Library in Primary Human Cell CoCulture Systems. Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA.  Houck, K., Use of primary human cell systems for creating predictive toxicology profiles. SBS Annual Meeting, 2009, Lille, France.  Houck, K. Evaluation of the ToxCast™ suite of cellular and molecular assay for prediction of in vivo toxicity. GlobalChem, 2009, Baltimore, MD.  Houck, K., Characteristics of the ToxCast™ In Vitro Datasets from Biochemical and Cellular Assays (EPA/ORD/NCCT). ToxCast™ Data Analysis Summit, May 14, 2009, RTP, NC. 12
  • 13.
    Contacts BioSeek, LLC 310 Utah, Suite 100 South San Francisco, CA 94030 650-416-7600 www.bioseekinc.com www.BioMAPSystems.com Bridging the Gap From In Vitro to In Vivo BioSeek, LLC 310 Utah, #100 South San Francisco, CA 94080